Onkológia 2/2018
Použitie rastových faktorov myelopoézy v profylaxii febrilnej neutropénie
Use of myelopoiesis growth factors in prophylaxis of febrile neutropenia Febrile neutropenia (FN) is characterized by a decrease in neutrophils number to values below 0.5 x 109/L and an occurrence of fever higher 38 °C. It commonly occurs in cancer patients as a result of chemotherapy regimens. Fever is one of the characteristic symptoms of FN. Neutropenia is a serious side effect of chemotherapy, affecting its dosage, and FN often requires prolonged hospitalization and treatment with broad spectrum antibiotics. It may cause dose decreases or delays in next chemotherapy cycle which could negatively affect treatment outcome. The incidence of FN is variable according to a multitude of factors such as the type of cancer, the age, and sex of the patient, and the type of treatment. The morbidity and mortality rates of FN have decreased over the years as a result of the use of appropriate antibiotic treatment, preventive measures, risk assessment procedures and adequate patient management plans.
Keywords: myelotoxicity, febrile neutropenia, growth factors
